NYSE:CRLLife Sciences
Charles River Laboratories NYSE CRL Quarterly Profit Streak Tests Bearish Profitability Narrative
Charles River Laboratories International (CRL) has just posted its FY 2025 third quarter numbers, with revenue of US$1,004.9 million and basic EPS of US$1.11, against a backdrop where trailing 12 month results still reflect a net loss on EPS. The company has seen quarterly revenue move between US$984.2 million and US$1,032.1 million over the first half of FY 2025, with basic EPS ranging from US$0.50 to US$1.06. Trailing 12 month revenue sits at about US$4.0 billion paired with a net loss of...